scholarly journals Temporal variations in maternal treatment requirements and early neonatal outcomes in patients with gestational diabetes

2021 ◽  
Author(s):  
Rachel A Fox ◽  
Charlotte J Patient ◽  
Abigail R. Aiken ◽  
Claire L Meek ◽  
Catherine E Aiken
Keyword(s):  
Gestational Diabetes ◽  
Temporal Variations ◽  
Neonatal Outcomes ◽  
Maternal Treatment

Gestational Diabetes: what to say about body mass index and outcomes? The influence of prepregnancy body mass index on obstetric and neonatal outcomes of women with gestational diabetes

2019 ◽  
Author(s):  
Sara Esteves Ferreira ◽  
Patricia Rosinha ◽  
Isabel Inacio ◽  
Marcia Alves ◽  
Teresa Azevedo ◽  
...  
Keyword(s):  
Body Mass Index ◽  
Gestational Diabetes ◽  
Body Mass ◽  
Neonatal Outcomes ◽  
Prepregnancy Body Mass Index

186-OR: Plasma Glycated CD59 (pGCD59) Predicts Early Gestational Diabetes (GDM) and Abnormal Neonatal Outcomes: DALI Study Secondary Analysis

Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 186-OR
Author(s):  
JOSE HALPERIN ◽  
DONGDONG MA ◽  
MIGUEL A. LUQUE-FERNANDEZ ◽  
DELIA BOGDANET ◽  
GERNOT DESOYE ◽  
...  
Keyword(s):  
Gestational Diabetes ◽  
Secondary Analysis ◽  
Neonatal Outcomes

Gestational diabetes mellitus: Glycemic control during pregnancy and neonatal outcomes of twin and singleton pregnancies

2018 ◽  
Vol 65 (6) ◽  
pp. 319-327
Author(s):  
María Augusta Guillén-Sacoto ◽  
Beatriz Barquiel ◽  
Natalia Hillman ◽  
María Ángeles Burgos ◽  
Lucrecia Herranz
Keyword(s):  
Diabetes Mellitus ◽  
Glycemic Control ◽  
Gestational Diabetes ◽  
Gestational Diabetes Mellitus ◽  
Neonatal Outcomes ◽  
Singleton Pregnancies

372: Gestational diabetes: does early screening improve neonatal outcomes?

2014 ◽  
Vol 210 (1) ◽  
pp. S189
Author(s):  
Veronica Alaniz ◽  
Emily Schneider ◽  
Sara Mazzoni ◽  
Norma Stiglich ◽  
M. Camille Hoffman
Keyword(s):  
Gestational Diabetes ◽  
Neonatal Outcomes ◽  
Early Screening

592: Treating mild gestational diabetes to improve maternal and neonatal outcomes: a cost effectiveness analysis

2011 ◽  
Vol 204 (1) ◽  
pp. S236
Author(s):  
Mika Ohno ◽  
Yvonne W. Cheng ◽  
Teresa N. Sparks ◽  
Sinae Vogel ◽  
Aaron B. Caughey
Keyword(s):  
Cost Effectiveness ◽  
Gestational Diabetes ◽  
Cost Effectiveness Analysis ◽  
Neonatal Outcomes ◽  
Effectiveness Analysis ◽  
Maternal And Neonatal Outcomes

Neonatal outcomes in case of euglycemic control in gestational diabetes using insulin versus metformin. Randomized controlled trial

2021 ◽  
Vol 04 (01) ◽  
pp. 01-08
Author(s):  
Ahmed Mansour
Keyword(s):  
Randomized Controlled Trial ◽  
Birth Weight ◽  
Gestational Diabetes ◽  
Controlled Trial ◽  
Insulin Injection ◽  
Neonatal Outcomes ◽  
Insulin Group ◽  
Randomized Controlled ◽  
Metformin Group ◽  
Significant Difference

Background: Gestational diabetes mellitus (GDM) is a major global public health issue, with prevalence increasing in recent years due to the epidemic of obesity and type 2 diabetes. Aim of the Work: to compare different neonatal outcomes according to the different treatment modalities used in the management of GDM. Our hypothesis was that Metformin is as effective and safe as insulin in patients with gestational diabetes. Patients and Methods: The current non inferiority-Randomized controlled trial was conducted at Ain Shams Maternity hospital between June 2020 to February 2021. The study included 140 outpatient cases or admitted patients for antenatal care: Group A: women were given Metformin (Total 70) and Group B: Women were given insulin. (Total 70). Results: there was no significant difference between Metformin and Insulin groups regarding age, enrollment BMI, parity and family history of DM. There was no significant difference between Metformin and Insulin groups regarding gestational age at enrollment and delivery as well as pregnancy duration after intervention. BMI at delivery, BMI increase as well as BMI increase rate were significantly lower in Metformin group. There were no significant differences between Metformin and Insulin groups regarding fasting, two-hour postprandial and HbA1c blood glucose at enrollment and throughout treatment as well as their reduction after intervention. Maternal complications as hypoglycemia, hyperglycemia and preeclampsia were non-significantly less frequent among Metformin group than among Insulin group. Compliance to treatment was significantly more frequent among Metformin group than among Insulin group. Cesarean delivery was non­significantly less frequent among Metformin group than among Insulin group. There was no significant difference between Metformin and Insulin regarding birth weight APGAR-1, but APGAR-5 was significantly higher in Metformin group. Neonatal complications as IUFD, IUGR, macrosomia, congenital anomalies, neonatal hypoglycemia, respiratory distress and NICU admission were non-significantly less frequent among Metformin group. Conclusions: From the results of current study we can conclude that: Oral metformin was effective as insulin injection in control and management of GDM. BMI was controlled with oral metformin better than insulin injection. Maternal and neonatal complications specially birth weight were the same with both types of treatment. Women had better compliance to metformin treatment. Type of delivery wasn’t affected by type of treatment.

scholarly journals Umbilical Cord Blood Acidosis in Term Pregnancies With Gestational Diabetes Mellitus and Its Relations to Maternal Factors and Neonatal Outcomes

2018 ◽  
Vol 20 (S1) ◽  
Author(s):  
Soroush Aalipour ◽  
Sedigheh Hantoushzadeh ◽  
Mamak Shariat ◽  
Sadaf Sahraian ◽  
Mahdi Sheikh
Keyword(s):  
Diabetes Mellitus ◽  
Gestational Diabetes ◽  
Gestational Diabetes Mellitus ◽  
Cord Blood ◽  
Umbilical Cord ◽  
Umbilical Cord Blood ◽  
Neonatal Outcomes ◽  
Maternal Factors

Neonatal adiposity following maternal treatment of gestational diabetes with glyburide compared with insulin

2009 ◽  
Vol 200 (5) ◽  
pp. 501.e1-501.e6 ◽  
Author(s):  
Kristine Y. Lain ◽  
Matthew J. Garabedian ◽  
Ashi Daftary ◽  
Arun Jeyabalan
Keyword(s):  
Gestational Diabetes ◽  
Maternal Treatment ◽  
Neonatal Adiposity

Perinatal Maternal and Neonatal Outcomes in Women With Gestational Diabetes Mellitus According to Fetal Sex

2012 ◽  
Vol 9 (6) ◽  
pp. 411-417 ◽  
Author(s):  
Diana Tundidor ◽  
Apolonia García-Patterson ◽  
Miguel A. María ◽  
Justa Ubeda ◽  
Gemma Ginovart ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Gestational Diabetes ◽  
Gestational Diabetes Mellitus ◽  
Neonatal Outcomes ◽  
Fetal Sex ◽  
Maternal And Neonatal Outcomes

P-646 Pregnancy outcomes in women with panhypopituitarism - A population-based study

2021 ◽  
Vol 36 (Supplement_1) ◽  
Author(s):  
I Feferkorn ◽  
A Badeghiesh ◽  
H Baghlaf ◽  
M Dahan
Keyword(s):  
Gestational Diabetes ◽  
Maternal Death ◽  
Pregnancy Outcomes ◽  
Post Partum ◽  
Population Based ◽  
Neonatal Outcomes ◽  
Pituitary Hormone ◽  
Population Based Study ◽  
Post Partum Hemorrhage

Abstract Study question What are the consequences of panhypopituitarism on pregnancy outcomes? Summary answer After controlling for confounding effects, women with panhypopituitarism have a higher prevalence of adverse obstetrical (including post-partum hemorrhage, hysterectomy and maternal death) and neonatal outcomes. What is known already Panhypopituitarism is a condition of inadequate or absent anterior pituitary hormone production. Pregnancy in women with panhypopituitarism is uncommon and there is only limited data (mainly case reports) regarding pregnancy outcomes in these women. Given the scarcity of data we sought to assess the association between panhypopituitarism and obstetrical and neonatal outcomes. Study design, size, duration A retrospective population-based study utilizing data from the Healthcare Cost and Utilization Project—Nationwide Inpatient Sample (HCUP-NIS). A dataset of all deliveries between 2004 and 2014 inclusively, was created. Within this group, all deliveries to women who had a diagnosis of panhypopituitarism during pregnancy were identified as part of the study group (n = 179), and the remaining deliveries comprised the reference group (n = 9,096,609). Participants/materials, setting, methods The HCUP-NIS is the largest inpatient sample database in the USA, and it is comprised of hospitalizations throughout the country. It provides information relating to 20% of US admissions and represents over 96% of the American population. Multivariate logistic regression analysis, controlling for confounding effects, was conducted to explore associations between panhypopituitarism and delivery and neonatal outcomes. According to Tri-Council Policy statement (2018), IRB approval was not required, given data was anonymous and publicly available. Main results and the role of chance Women with a diagnosis of panhypopituitarism were more likely to be older, to have a diagnosis of chronic hypertension, to have a diagnosis of pre-gestational diabetes mellitus and to be carrying twins or a higher order pregnancy (all p < 0.0001), than the controls. A significantly higher risk of post-partum hemorrhage (adjusted odds ratio-aOR:3.52; 95%CI:2.18–5.69,p < 0.0001), maternal infection (aOR:3.97; 95%CI:2.30–6.85,p < 0.0001), pulmonary embolism (aOR:14.90; 95%CI:2.06–107.82,p < 0.007), disseminated intravascular coagulation (aOR:20.29; 95%CI:10.60–38.85,p < 0.0001), maternal death (aOR:31.90; 95%CI:3.33–234.85,p = 0.001) and congenital anomalies (aOR:4.55; 95CI:1.86–11.16,p = 0.001), were found among the panhypopituitarism patients. Surprisingly, there was a lower incidence of caesarean delivery (aOR:0.69; 95%CI:0.50–0.96,p = 0.026) in the panhypopituitarism patients than the controls. No significant difference was found in the rate of pregnancy induced hypertension (95%CI:0.78-1.97), gestational hypertension (95%CI:0.14-1.41), preeclampsia (95%CI:0.96-2.99), gestational diabetes (95%CI:0.30-1.01), preterm delivery (95%CI:0.74-1.91), preterm premature rupture of membranes (95%CI:0.17-2.82), operative vaginal delivery (95%CI: 0.23-1.19), small for gestational age neonates (95%CI:0.27-2.02) or intra-uterine fetal demise (95%CI:0.13-6.71). Limitations, reasons for caution The limitations of our study are its retrospective nature and the fact that it relies on an administrative database. The severity of specific hormonal deficiencies and the presence and magnitude of posterior pituitary hormone deficiencies could not be assessed, nor could compliance with hormone replacement. Wider implications of the findings Until now, no control studies of outcomes with panhypopituitaryism in pregnancy are available in the medical literature. Physicians should be aware of and try to prevent the above possible maternal and fetal complications related to this endocrinopathy. Future studies should evaluate the role of medication compliance with pregnancy outcomes. Trial registration number not applicable

Sign in / Sign up

Export Citation Format

Share Document